| A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea … M Aapro, H Rugo, G Rossi, G Rizzi, ME Borroni, I Bondarenko, T Sarosiek, ... Annals of oncology 25 (7), 1328-1333, 2014 | 277 | 2014 |
| Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial V Diéras, HS Han, B Kaufman, H Wildiers, M Friedlander, JP Ayoub, ... The lancet oncology 21 (10), 1269-1282, 2020 | 267 | 2020 |
| Updated overall survival analysis from IMpower110: Atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1–selected NSCLC J Jassem, F de Marinis, G Giaccone, A Vergnenegre, CH Barrios, ... Journal of Thoracic Oncology 16 (11), 1872-1882, 2021 | 116 | 2021 |
| Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in squamous cell carcinoma of the head and neck (MEHGAN Study) J Fayette, L Wirth, C Oprean, A Udrea, A Jimeno, D Rischin, C Nutting, ... Frontiers in oncology 6, 232, 2016 | 90 | 2016 |
| Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer VC Dieras, HS Han, B Kaufman, H Wildiers, M Friedlander, JP Ayoub, ... Annals of Oncology 30, v857-v858, 2019 | 58 | 2019 |
| NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results … M Aapro, M Karthaus, L Schwartzberg, I Bondarenko, T Sarosiek, ... Supportive Care in Cancer 25, 1127-1135, 2017 | 55 | 2017 |
| Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study … J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ... European Journal of Cancer 82, 237-246, 2017 | 51 | 2017 |
| Randomized phase II study of Mehd7945a (mehd) vs cetuximab (cet) in>= 2nd-line recurrent/metastatic squamous cell carcinoma of the head & neck (rmscchn) progressive on/after … J Fayette, LJ Wirth, C Oprean, R Hitt, A Udrea, A Jimeno, D Rischin, ... Annals of Oncology 25, iv340, 2014 | 32 | 2014 |
| The influence of cognitive schemas on the mixed anxiety-depressive symptoms of breast cancer patients AC Bredicean, Z Crăiniceanu, C Oprean, IA Riviș, I Papavă, I Secoșan, ... BMC Women's Health 20, 1-10, 2020 | 23 | 2020 |
| Well-being, depression, and anxiety following oncoplastic breast conserving surgery versus modified radical mastectomy followed by late breast reconstruction D Grujic, C Giurgi-Oncu, C Oprean, Z Crăiniceanu, I Secoșan, I Riviș, ... International Journal of Environmental Research and Public Health 18 (17), 9320, 2021 | 12 | 2021 |
| Effectiveness and safety profile of ipilimumab therapy in previously treated patients with unresectable or metastatic melanoma–The Romanian Patient Access Program DC Jinga, T Ciuleanu, S Negru, C Aldea, L Gales, F Bacanu, C Oprean, ... J BUON 22, 1287-1295, 2017 | 11 | 2017 |
| FP13. 03 IMpower110: updated OS analysis of atezolizumab vs platinum-based chemotherapy as first-line treatment in PD-L1–selected NSCLC R Herbst, F De Marinis, G Giaccone, A Vergnenegre, C Barrios, M Morise, ... Journal of Thoracic Oncology 16 (3), S224-S225, 2021 | 10 | 2021 |
| No evidence of increased cyclophosphamide toxicity associated with the antiemetic agent NEPA, a fixed-dose combination of netupitant and palonosetron L Schwartzberg, C Oprean, S Cardona-Huerta, G Rizzi, G Rossi, ... Blood 122 (21), 2949, 2013 | 8 | 2013 |
| Spectrum of BRCA1/2 mutations in romanian breast and ovarian cancer patients R Vidra, TE Ciuleanu, A Nemeș, O Pascu, AM Heroiu, N Antone, ... International Journal of Environmental Research and Public Health 19 (7), 4314, 2022 | 7 | 2022 |
| Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study. U Keilholz, A Kawecki, A Dietz, B Zurawski, M Schenker, ... Journal of Clinical Oncology 36 (5_suppl), 59-59, 2018 | 7 | 2018 |
| Postmenopausal Breast Cancer in Women, Clinical and Epidemiological Factors Related to the Molecular Subtype: A Retrospective Cohort Study in a Single Institution for 13 Years … THAD Cristina Marinela Oprean , Serban Mircea Negru , Dorel Ionel Popovici ... Int. J. Environ. Res. Public Health 17 (23), 8722, 2020 | 6 | 2020 |
| Unilateral orbital metastasis as the unique symptom in the onset of breast cancer in a postmenopausal woman: case report and review of the literature CM Oprean, LM Badau, NA Segarceanu, AD Ciocoiu, IA Rivis, ... Diagnostics 11 (4), 725, 2021 | 5 | 2021 |
| Endurance of erythrocyte series in chemotherapy S Săftescu, D Popovici, C Oprean, A Negru, A Croitoru, M Zemba, I Yasar, ... Experimental and Therapeutic Medicine 20 (6), 1-1, 2020 | 5 | 2020 |
| Patient‐reported outcomes in the randomized, phase III IMpower110 study of atezolizumab vs chemotherapy in 1L metastatic NSCLC F De Marinis, G Giaccone, RS Herbst, C Oprean, A Szczesna, ... J Clin Oncol 38 (Suppl l), 9594, 2020 | 5 | 2020 |
| Perception of disease, dyadic coping, and the quality of life of oncology patients in the active treatment phase and their life partners: an approach based on the actor-partner … AM Ștefănuț, M Vintilă, LM Bădău, D Grujic, CM Oprean, C Goian, ... Frontiers in Psychology 14, 1069767, 2023 | 4 | 2023 |
